Today, ExpreS2ion Biotechnologies could announce that they together with partners have been awarded a grant with the The aim is to obtain clinical proof-of-concept of a Nipah virus (NiV) vaccine candidate within four years. The total grant is amounting to 8 million EUR, approximately 90 million S EK, to the VICI-Disease consortium, of which 53% is direct contribution for ExpreS2ion’s part of the project costs. https://view.news.eu.nasdaq.com/view?id=b2efd867524d809a6623e12e8790fd4d6&lang=en&src=listed The grant represents a not insignificant non-dilutive funding of the cost base in the coming years and is first good sign to investors to understand the new business model, which is about leveraging their product platform to go after assets with shorter development timelines and maybe more importantly with a path to value creation without need for diluting funding. ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system. Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis 14.45, 16 November 2023.

info@inderes.fi (inderes.fi)

© Inderes Oyj. All rights reserved.